ArticleBMJ case reports2021
Successful treatment of smouldering Human T cell Leukemia Virus Type1 associated bronchiolitis and alveolar abnormalities with amplified natural killer therapy.
Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Long-Term Survival of Patients with Adult T-Cell Leukemia/Lymphoma Treated with Amplified Natural Killer Cell Therapy.Reports (MDPI) · 2024Article
- ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease.Cancer medicine journal · 2023Article
- Effectiveness of Amplified Natural Killer (ANK) Therapy for Adult T-cell Leukemia/Lymphoma (ATL) and Future Prospects of ANK Therapy.Cancer medicine journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In amplified natural killer (ANK) cell immunotherapy, NK cells are extracted from the patient's blood, cultured for enhancing its anticancer effects and amplified before they are returned to the body. Here, we administered ANK therapy to an 81-year-old female patient diagnosed with smouldering human T cell leukaemia virus-associated bronchioloalveolar disorder. After eight sessions of twice-weekly NK cell infusion, the bilateral diffuse granular shadows on a CT scan and the overall respiratory function improved markedly. Later, the patient received outpatient treatment without serious side effects. Thus, ANK therapy may be safe for elderly patients owing to its infrequent side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.